Glycomimetics Stock Price, News & Analysis

GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Harout Semerjian will participate in the Leukemia Panel at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Wednesday, March 8, 2023, at 12:50 p.m. ET.

A live webcast will be available on GlycoMimetics' website, and an archived recording will be accessible for 30 days post-event.

As a leading biotechnology firm, GlycoMimetics focuses on developing innovative therapies targeting cancers and inflammatory diseases through its specialized glycomimetics platform.

GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a non-qualified stock option award for 150,000 shares to Chinmaya Rath, the new Senior Vice President and Chief Business Officer, approved by the Compensation Committee on February 10, 2023. The award serves as an inducement for employment outside the Company’s Amended and Restated 2013 Equity Incentive Plan, compliant with NASDAQ Listing Rule 5635(c)(4). The options vest over four years, starting with 25% on February 10, 2024, and carry an exercise price of $3.48, reflecting the closing stock price on the grant date.

GlycoMimetics (Nasdaq: GLYC) has received a positive recommendation from the independent Data Monitoring Committee to continue its pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML). The study is on track for a final overall survival event trigger expected in the first half of 2024. Interim analysis shows patients are living longer than historical benchmarks. Additionally, the company raised $32.9 million via an at-the-market facility, extending its cash runway into Q4 2024, supporting further clinical development and potential commercialization of uproleselan.

GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a non-qualified stock option to new Vice President, Commercial Operations, Debora Peralta, on January 31, 2023. The award totals 100,000 shares of common stock, with an exercise price of $2.91 per share. Vesting occurs as 25% on January 31, 2024, followed by monthly installments over 36 months. This grant adheres to NASDAQ Listing Rule 5635(c)(4) and is considered an inducement for Peralta's employment. GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases with high unmet needs.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced promising results from two investigator-sponsored trials of uproleselan in acute myeloid leukemia (AML) patients, showcased at the 64th ASH Annual Meeting. Preliminary data reveal an overall response rate of 62% in treated secondary AML with uproleselan combined with cladribine and low-dose cytarabine. Another trial showed a 75% CR/CRi rate with uproleselan, azacitidine, and Venetoclax in older or unfit patients. Both trials present safety and efficacy insights, as enrollment continues.

The U.S. FDA has approved an amendment for an interim utility analysis of GlycoMimetics' Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML). Blinded pooled survival data indicate patients are living longer than historical expectations. The Data Monitoring Committee (DMC) will decide by the end of Q1 2023 if the study continues or unblinds for full analysis. As of September 30, 2022, cash and equivalents were $51.6 million, with a cash runway extended through year-end 2023 due to reduced expenses.

GlycoMimetics, Inc. (Nasdaq: GLYC) will participate in two investor conferences: the Stifel 2022 Healthcare Conference on November 15, 2022, hosting 1x1 investor meetings, and the Jefferies London Healthcare Conference on November 17, 2022, featuring a fireside chat at 10:50 a.m. EST. An archived recording of the fireside chat will be available for 90 days on their website. GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, leveraging its unique approach to advance drug candidates.

GlycoMimetics, Inc. (NASDAQ: GLYC) announced acceptance of data from two investigator-sponsored trials studying uproleselan in acute myeloid leukemia (AML) for presentation at the 64th American Society of Hematology Annual Meeting. Uproleselan is a targeted E-selectin inhibitor currently in Phase 3 development. Initial results emphasize its safety and preliminary efficacy for both frontline unfit and treated secondary AML patients. This marks the first clinical data outside company-sponsored studies, potentially enhancing treatment options for heterogeneous AML populations.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced a conference call for its third quarter financial results on November 9, 2022, at 8:30 a.m. ET. Interested participants can register via a provided link to access dial-in details and are encouraged to join 15 minutes early. The call will also be available through a live webcast on the company’s website, with a replay offered for 30 days. GlycoMimetics specializes in glycobiology-based therapies for cancers and inflammatory diseases, leveraging its unique small molecule drugs to develop transformative therapies.